Biosimilars Caught In Crosshairs Of Supreme Court ACA Fight
Law360 (November 9, 2020, 8:24 PM EST) -- The U.S. Supreme Court is set to hear oral arguments Tuesday in a case challenging the Affordable Care Act, and while all eyes have been focused on whether conservative justices will strike down former President Barack Obama's landmark health insurance expansion, a critical provision governing biosimilars is also at stake.
The Biologics Price Competition and Innovation Act, which was passed as Title VII of the ACA, provides a regulatory pathway for similar or copycat versions of patent-protected biologics to get to market, comparable to the Hatch-Waxman Act for small-molecule drugs. If the entire act is found to be unconstitutional, then biosimilar makers will face...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!